Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Manufacturing

Set Alert for Manufacturing

Probable Carcinogen Found Haunting More Firms’ Valsartan API

As Zhejiang Huahai works to rid its valsartan API manufacturing process of NDMA impurity, two competitors also have launched recalls after discovering the probable carcinogen in their valsartan API. Meanwhile, US FDA confronts Huahai over handling of impurities that visited chromatograms in the form of ghost peaks.

Manufacturing Quality Recalls
Advertisement

Latest From Manufacturing

The Quality Lowdown: A Week Of International Intrigue

Or perhaps it's been a week of intriguing international events in global drug quality, as an international group works to ratchet up global standards, regulators aim to ease the coming UK/EU divorce and the US and China play their hands in a tariff poker match. Meanwhile, US FDA looks to avert labeler code crisis, Quebec API firm comes clean about missing identity testing, and US firm recalls drug product based on FDA’s API supplier inspection findings.

Quality Manufacturing

Chinese API Maker Blasted For Failing To Document Equipment Cleaning And Lax Stability Testing Practices

FDA chastised Chinese API maker for inadequate cleaning validation, failing to ensure that products are manufactured in a state of control, and lax stability testing practices. The agency noted that the firm did not learn from observations the agency made of similar mistakes during previous inspections.

United States Manufacturing

FDA's Final Guideline Standardizes Dissolution Testing For Highly Soluble Drugs

FDA guidance aims to establish uniform dissolution testing methods for highly soluble immediate-release solid oral dosage forms.

Manufacturing Quality

FDA Says Shipping Logistics Should Be Priority For Cell Therapy Products

FDA says manufacturers need robust shipping programs to ensure the safety and quality of cell therapies, since there are no ready replacements and a patient’s life can be at risk if problems arise. Kite exec notes that “more than any other biologic, the supply chain of autologous cell therapies reaches really literally end-to-end.”

United States Manufacturing

CAR-T Cells Addressed In Updated EMA Guide On Drugs Containing Genetically-Modified Cells

The European Medicines Agency's current thinking on the clinical development of CAR-T cells is outlined in a new annex.
Europe Manufacturing

Quality Expert Urges Firms To Adopt QbD Approach When Developing Cell Therapies

Expert explains how firms can leverage pharmaceutical quality-by-design principles when developing cell therapies to help make sure their manufacturing processes remain in a state of control over the product lifecycle.

Manufacturing Quality
See All
UsernamePublicRestriction

Register